Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL  Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences, Inc.

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated

FiercePharma provides news and information related to the pharmaceutical industry, including topics like vaccines, drug delivery, and manufacturing, self-described as highlighting corporations driving change in healthcare.

FiercePharma

Neurocrine Biosciences is involved in neurology and endocrinology research and therapy, focusing on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, self-described as addressing unmet medical needs.

Metric
Company Name	Neurocrine Biosciences, Inc.	Biotech 365	Corcept Therapeutics Incorporated	FiercePharma
Symbol	NBIX		CORT
MSH ID	COM:NEUROCRINE	COM:BIOTECH-365	COM:CORCEPT	COM:FIERCEPHARMA
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Financial Services & Finance	Healthcare	Commercial & Professional Services
Industry	Drug Manufacturers - Specialty & Generic	Biotechnology Business Services	Biotechnology	Pharmaceuticals
Country	US	FR	US	US
Stage
Employee Count	1.45K		352
Website	neurocrine.com	biotech-365.com	corcept.com	fiercepharma.com
LinkedIn
Founders

Metric
Market Cap	14.81B		3.19B
Enterprise Value
Monthly Web Traffic	11.48K	68	53.48K	484.53K
Web Traffic Growth	0.19	-0.57	3.98	-0.10
Valuation
Raised Capital

Metric
Revenue	1.89B	482.38M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.85B	475.89M
EBITDA	250.90M	109.64M
Operating Income	250.90M	107.28M
Net Income	249.70M	106.14M
EPS	2.56	1.02
Diluted EPS	2.47	0.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98	0.99
Operating Profit Margin	0.26	0.23
EBITDA Margin	0.13	0.23
Net Profit Margin	0.19	0.23
Return on Equity	0.17	0.24
Return on Assets	0.11	0.18
Return on Capital Employed	0.19	0.22

COM:NEUROCRINE

Neurocrine Biosciences

Last Close

125.00

22/11 21:00

Market Cap

14.81B

Beta: -

Volume Today

1.18M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	72.61	24.15
P/B Ratio	6.93	4.78
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.54	9.13
EV Multiple	35.09	41.21

Metric
Days Sales Outstanding	85.49	39.44
Days Payables Outstanding		1.00K
Days Inventory Outstanding	372.00	435.27
Operating Cycle	452.63	476.98
Cash Conversion Cycle	452.63	-212.43
Asset Turnover	0.64	0.80

Metric
Operating Cash Flow	389.90M	127.04M
Free Cash Flow	361.60M	126.90M
Cash Flow to Debt	2.52	1.64K
Operating Cash Flow/Sales	0.33	0.26
Free Cash Flow Yield	0.03	0.07

Metric
Cash & Equivalents	251.10M	135.55M
Accounts Receivable	-89.30M	-10.07M
Inventory	38.30M	7.73M
Goodwill
Debt to Capitalization	0.19	0.01
Debt to Assets	0.09	0.00
Current Ratio	2.39	3.54
Quick Ratio	4.08	5.48

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11	0.10
R&D to Revenue	0.31	0.37
SG&A to Revenue